# Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients (COVIDSOT) (COVID-19)

First published: 30/03/2020

**Last updated:** 31/03/2020





### Administrative details

EU PAS number	
EUPAS34349	
Study ID	
-	
34406	
DARWIN EU® study	
No	
Study countries	
Italy	
United Kingdom	

#### Study description

The overall purpose of this project is to better understand the incidence, risk factors, etiology, clinical manifestations and outcome of tCOVID19 in solid organ transplant recipients. The results obtained will allow us to gain insight on the need of antiviral treatment, on the strategy for complications surveillance, on how to adjust the immunosuppressant therapy and on the level of care in which each patient should be treated. In order to attain the objectives previously described we will develop a multicenter prospective study of consecutive cases of COVID-19 among solid organ transplant recipients. Length of viral shedding and immunological response will be also studied. There will be a clinical follow-up of the patients included in this study to observe possible complications and survival rate. For those centers who cannot recover biological samples, only clinical data will be included. Data collected form this study will be evaluated with a descriptive statistical analysis of the cohort consisting of a univaried analysis of the risk factors of COVID-19. Subsequently a multivaried logistic regression analysis will be performed in which the factors selected from the univaried analysis and those clinically relevant.

### Study status

Ongoing

### Research institutions and networks

### Institutions

## Hospital Universitario Virgen del Rocío

First published: 01/02/2024

**Last updated:** 01/02/2024



### **Networks**

**REIPI** 

### Contact details

### **Study institution contact**

Elisa Cordero mariae.cordero.sspa@juntadeandalucia.es

 $\Big($  Study contact  $\Big)$ 

mariae.cordero.sspa@juntadeandalucia.es

### Primary lead investigator

Elisa Cordero

**Primary lead investigator** 

## Study timelines

Date when funding contract was signed

Planned: 13/03/2020

Actual: 13/03/2020

#### Study start date

Planned: 20/03/2020

Actual: 20/03/2020

#### **Date of final study report**

Planned: 13/03/2022

## Sources of funding

• Other

## More details on funding

**ISCIII** 

## Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

## Methodological aspects

Study type

Study type list

#### Study type:

Non-interventional study

#### Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Disease epidemiology

Drug utilisation

Effectiveness study (incl. comparative)

### Main study objective:

To know the incidence, clinical manifestations and outcome of infections of COVID-19 on Solid Organ Transplant Recipients

## Study Design

### Non-interventional study design

Cohort

## Study drug and medical condition

#### Medical condition to be studied

Solid organ transplant

## Population studied

#### **Age groups**

• Adults (18 to < 46 years)

- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)</li>
- Adults (85 years and over)

#### Special population of interest

Renal impaired
Hepatic impaired
Immunocompromised

#### **Estimated number of subjects**

50

## Study design details

#### **Outcomes**

1. Incidence of coronavirus infection in Solid Organ Transplant Recipients2. Clinical manifestations of coronavirus infection in Solid Organ Transplant Recipients 3. Presence of other risk factors4. Establish the frequency and type of complications related to the net state of the patientimmunosuppression, 1. Frequency of co-infections2. Mortality3. Laboratory characteristics4. Determination of coronavirus viral load5. Microbiological testing

#### **Data analysis plan**

Results obtained during the study will be analyzed using the SPSS statistical software (version 15.0, SPSS Inc, Chicago, Illinois). A descriptive analysis of all data obtained will be performed. In order to detect significant differences between groups, a Chi-square or a Fisher exact test in the case of categorical variables and the t or a Mann-Whitney test for continuous variables will be applied. Furthermore, a linear trend analysis will also be used, in the case of

multiple comparisons. In the multivariate analysis all the variable related to un unfavorable outcome in the unvaried analyses and those, that are clinically relevant significant, will be included.

### Data management

### **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### Data sources

### **Data sources (types)**

Administrative healthcare records (e.g., claims)

Disease registry

Drug dispensing/prescription data

Other

### Data sources (types), other

Prospective patient-based data collection, Prescription event monitoring

## Use of a Common Data Model (CDM)

### **CDM** mapping

No

## Data quality specifications

### **Check stability**

**Check conformance** 

Unknown

### **Check logical consistency**

Unknown

## Data characterisation

#### **Data characterisation conducted**

No